SOURCE: Herborium Group, Inc.

The Healing Power of Botanical Therapeutics

June 15, 2010 11:07 ET

Herborium Group Names Dr. Harold Mermelshein MD to Its Scientific Advisory Board

SADDLE BROOK, NJ--(Marketwire - June 15, 2010) -  Herborium Group, Inc. (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced the appointment of Dr. Harold Mermelshein, MD, a renowned New York dermatologist, to Herborium's Scientific Advisory Board.

"I'm pleased that such a prestigious dermatologist as Dr. Mermelshein has agreed to serve on our Scientific Advisory Board," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer. "Dr. Mermelshein's career spans more than 30 years, during which time he has distinguished himself as a dedicated, learned advocate in dermatological academia, research, and clinical practice as well as pioneer in using complementary, scientifically based, alternative treatment modalities in clinical practice."

Dr. Mermelshein is Board Certified by, and a standing member of, the American Academy of Dermatology. A magna cum laude alumnus of New York Medical College. Dr. Mermelshein has served as Chief of Residency for New York University Medical Center's Skin and Cancer Unit and, since 1988, as the Associate Clinical Professor of the Center Dermatology Department.

Dr. Olszewski continued, "With Herborium's flagship product, AcnEase®, now available through an increasing number of distribution channels in the US and abroad, we are focusing on strengthening its consumer and professional brand recognition. Dr. Mermelshein will play a key role in meeting and maintaining only the highest standards expected by medical professionals and consumers, further strengthening Herborium's differential brand advantage. To that end, he will advise management regarding the Company's proactive clinical validation and regulatory strategy speared the U.S. Food and Drug Administration's (FDA) guidance for the botanical drug product industry (FDA Guidance 2004)."

"With Herborium's business model based on clinical testing confirmation of our products efficacy, having Dr. Mermelshein among our team of medical experts will also facilitate further advancement of our clinical testing, and therefore strengthen a differential advantage and marketability of our products growing," concluded Dr. Olszewski.

About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.

Contact Information

  • Company Contact:
    Dr. Agnes P. Olszewski
    President & CEO
    (201) 647-3757